Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
    • Editorial Fellowship Application Process
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
    • Editorial Fellowship Application Process
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Letters to the Editor
You have accessRestricted Access

Authors’ Reply

Magdalene M. Assimon and Jennifer E. Flythe
JASN July 2019, 30 (7) 1340; DOI: https://doi.org/10.1681/ASN.2019040431
Magdalene M. Assimon
1University of North Carolina Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, UNC School of Medicine, Chapel Hill, North Carolina; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer E. Flythe
1University of North Carolina Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, UNC School of Medicine, Chapel Hill, North Carolina; and
2Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • hemodialysis
  • SSRIs
  • depression
  • safety
  • sudden cardiac death

We thank Chilcot and Farrington1 for their interest in our paper2 and thoughtful comments surrounding the treatment of depression in hemodialysis patients. We agree with the letter writers that our observational study was not designed to evaluate the effect of antidepressant pharmacotherapy (versus no treatment) on mortality among individuals with hemodialysis-dependent ESRD. Under our active comparator new-user design, we could only conclude that the initiation of a higher (citalopram and escitalopram) versus lower (fluoxetine, fluvoxamine, paroxetine, and sertraline) QT-prolonging potential selective serotonin reuptake inhibitor (SSRI) was associated with a higher risk of sudden cardiac death.2 Our study was designed to reflect a clinician’s decision to prescribe an SSRI with higher versus lower QT-prolonging potential to a hemodialysis patient (i.e., a treatment choice encountered in real-world practice).2–4 The study provides population-specific safety information that clinicians can consider when prescribing SSRI therapy to hemodialysis patients.

Disclosures

Dr. Assimon and Dr. Flythe have received investigator-initiated research funding from the Renal Research Institute, a subsidiary of Fresenius Medical Care, North America. In the last 2 years, Dr. Flythe has received speaking honoraria from American Renal Associates; the American Society of Nephrology; Dialysis Clinic, Inc.; the National Kidney Foundation; and multiple universities. Dr. Flythe is on the medical advisory board of NxStage Medical, Inc. and has received consulting fees from Fresenius Medical Care, North America.

Acknowledgments

Dr. Assimon and Dr. Flythe are supported by grant R03 HS026801 from the Agency for Healthcare Research and Quality. Dr. Flythe is supported by grant K23 DK109401 from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • See related Letters to the Editor, “The Case for Selective Withdrawal of Antidepressants in Patients with Advanced Kidney Disease,” on pages 1339–1340.

  • Copyright © 2019 by the American Society of Nephrology

References

  1. ↵
    1. Chilcot
    J, Farrington K: The case for selective withdrawal of antidepressants in patients with advanced kidney disease. J Am Soc Nephrol 30: 1339, 2019pmid:30885935
    OpenUrlFREE Full Text
  2. ↵
    1. Assimon MM,
    2. Brookhart MA,
    3. Flythe JE
    : Comparative cardiac safety of selective serotonin reuptake inhibitors among individuals receiving maintenance hemodialysis. J Am Soc Nephrol 30: 611–623, 2019pmid:30885935
    OpenUrlAbstract/FREE Full Text
    1. Velentgas P,
    2. Dreyer NA,
    3. Nourjah P,
    4. Smith SR,
    5. Torchia MM
    , editors: Developing a Protocol for Observational Comparative Effectiveness Research: A User’s Guide, Rockville, MD, Agency for Healthcare Research and Quality, 2013
  3. ↵
    1. Brookhart MA
    : Counterpoint: The treatment decision design. Am J Epidemiol 182: 840–845, 2015pmid:26507307
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 30 (7)
Journal of the American Society of Nephrology
Vol. 30, Issue 7
July 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Authors’ Reply
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Authors’ Reply
Magdalene M. Assimon, Jennifer E. Flythe
JASN Jul 2019, 30 (7) 1340; DOI: 10.1681/ASN.2019040431

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Authors’ Reply
Magdalene M. Assimon, Jennifer E. Flythe
JASN Jul 2019, 30 (7) 1340; DOI: 10.1681/ASN.2019040431
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Roxadustat for Renal Anemia in ESRD from PKD Patients: Is It Safe Enough?
  • Authors’ Reply
  • Authors' Reply
Show more Letters to the Editor

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • The Case for Selective Withdrawal of Antidepressants in Patients with Advanced Kidney Disease
  • PubMed
  • Google Scholar

Keywords

  • hemodialysis
  • SSRIs
  • depression
  • safety
  • sudden cardiac death

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire